On October 20, 2025, Autolus Therapeutics plc announced that the first patient has been dosed in its Phase 1 BOBCAT trial of the CD19 CAR‑T therapy obe‑cel for progressive multiple sclerosis (PMS). The dosing took place at University College London Hospitals NHS Foundation Trust in London, marking the first clinical exposure of the drug in an autoimmune indication.
The BOBCAT study is designed to enroll up to 18 adult patients and will assess safety, tolerability, and preliminary efficacy of obe‑cel in refractory PMS. The trial’s primary endpoint is safety and tolerability, with secondary measures including changes in standard efficacy scales and biological markers of CNS inflammation.
This milestone expands Autolus’s pipeline into a high‑unmet‑need autoimmune market, positioning the company to pursue regulatory approval for a one‑time treatment in PMS. The successful initiation of the trial signals progress toward potential future approvals and underscores the strategic importance of the autoimmune platform for long‑term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.